Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.
Hyperfine Inc (HYPR) pioneers accessible MRI technology through its groundbreaking Swoop® Portable MR Imaging System, transforming diagnostic capabilities in critical care and underserved settings. This page serves as the definitive source for verified news and announcements related to corporate developments, clinical milestones, and financial performance.
Investors and healthcare professionals will find timely updates on regulatory clearances, partnership agreements, quarterly earnings, and technological advancements. Our curated collection includes press releases about device deployments, peer-reviewed study results, and strategic initiatives driving portable MRI adoption.
Key coverage areas include Swoop system innovations, financial results analysis, leadership updates, and market expansion efforts. All content is rigorously verified to ensure accuracy and relevance for stakeholders evaluating HYPR's position in the medical imaging sector.
Bookmark this page for streamlined access to Hyperfine's latest progress in redefining bedside diagnostics through ultra-low-field MRI technology. Check regularly for objective reporting on developments impacting both clinical practice and long-term corporate strategy.
Hyperfine, a health technology company known for its FDA-cleared portable MR brain imaging system, the Swoop®, will present at the Jefferies Global Healthcare Conference in New York on June 6, 2024, at 3:00 pm ET. The event will be live-streamed and archived on the company's investor relations website for 90 days. For more details about the Swoop® system, visit their official website.
Hyperfine (Nasdaq: HYPR) participated in the 2024 ASNR Annual Meeting held in Las Vegas from May 18-22, 2024. The event highlighted the use of the Swoop® Portable MR Imaging® system, particularly for Alzheimer's care. Presenters emphasized the critical role of MRI in diagnosing and managing Alzheimer's disease and the potential of portable MR imaging to fill existing gaps in diagnostic capabilities. Sessions focused on the importance of monitoring amyloid-related imaging abnormalities (ARIA) for safe Alzheimer’s treatments. Attendees expressed significant enthusiasm for the Swoop® system’s benefits in clinical settings.
Hyperfine (Nasdaq: HYPR) announced its Q1 2024 financial results on May 13, 2024. The company reported $3.30 million in revenue, a 25% increase from Q1 2023, and sold 13 Swoop® systems. Gross margin improved to $1.35 million. R&D expenses were $5.57 million, and SG&A expenses dropped to $6.43 million. Net loss decreased to $9.85 million ($0.14 per share) from $12.16 million ($0.17 per share) in Q1 2023. Key milestones include starting the CARE PMR Alzheimer’s study, enrolling over 100 patients in the ACTION PMR stroke study, and launching the 8th-gen AI-powered software. Full-year 2024 revenue is expected to be $12-$15 million with a $40 million cash burn.
Hyperfine, Inc. (Nasdaq: HYPR) has appointed distributors in France, the UK, and Italy to expand the market reach of its portable MR brain imaging system, Swoop®. The company has obtained CE certification and UKCA certification for its latest hardware and AI-powered software. The move aims to meet the global demand for accessible MR brain imaging, with a focus on Alzheimer's disease and acute stroke applications. Enrico Barini joins as International Business Development Director to lead the European market expansion.
Hyperfine, Inc. (Nasdaq: HYPR) will announce its first quarter 2024 financial results on May 13, 2024. The company, known for its FDA-cleared portable MR brain imaging system, the Swoop® system, will host a conference call on the same day. The event can be accessed via the Investors page of Hyperfine, Inc.'s website.
FAQ
What is the current stock price of HYPERFINE (HYPR)?
What is the market cap of HYPERFINE (HYPR)?
